NTLA

13.82

1.58% 0.215

Pre-mercato: 13.53 -0.29 -2.10%

Intellia Therapeutics Inc (NTLA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$13.61

Aprire:

$13.98

Volume 24 ore:

5.88M

Relative Volume:

1.24

Capitalizzazione di mercato:

$1.60B

Reddito:

$52.86M

Utile/perdita netta:

$-480.19M

Rapporto P/E:

-2.9468

EPS:

-4.6899

Flusso di cassa netto:

$-421.82M

1 W Prestazione:

+2.98%

1M Prestazione:

+11.81%

6M Prestazione:

+18.93%

1 anno Prestazione:

+51.95%

Intervallo 1D:

$13.41

$14.12

Intervallo di 1 settimana:

$12.70

$15.51

Portata 52W:

$5.90

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Nome

Intellia Therapeutics Inc

Settore

Healthcare (1106)

Industria

Biotechnology (621)

Telefono

857-285-6200

Indirizzo

40 ERIE STREET, CAMBRIDGE, MA

Dipendente

598

Cinguettio

@intelliatweets

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NTLA Intellia Therapeutics Inc	13.82	1.58B	52.86M	-480.19M	-421.82M	-4.6899
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-12	Downgrade	Wolfe Research	Outperform → Peer Perform
2025-11-11	Downgrade	Evercore ISI	Outperform → In-line
2025-11-07	Downgrade	JP Morgan	Neutral → Underweight
2025-10-28	Downgrade	Bernstein	Outperform → Mkt Perform
2025-10-28	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-10-27	Downgrade	Guggenheim	Buy → Neutral
2025-10-27	Downgrade	William Blair	Outperform → Mkt Perform
2025-10-06	Aggiornamento	Citizens JMP	Mkt Perform → Mkt Outperform
2025-04-21	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-03-05	Iniziato	H.C. Wainwright	Buy
2025-02-28	Downgrade	Goldman	Neutral → Sell
2025-02-28	Downgrade	JP Morgan	Overweight → Neutral
2025-01-27	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2024-02-23	Downgrade	Goldman	Buy → Neutral
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2023-04-13	Iniziato	Canaccord Genuity	Buy
2023-03-21	Iniziato	Bernstein	Outperform
2023-03-14	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-02-01	Iniziato	Cantor Fitzgerald	Overweight
2023-01-24	Aggiornamento	Citigroup	Sell → Neutral
2023-01-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2022-10-11	Iniziato	Morgan Stanley	Overweight
2022-09-21	Iniziato	JP Morgan	Overweight
2022-09-01	Iniziato	Citigroup	Sell
2022-06-17	Iniziato	BMO Capital Markets	Market Perform
2022-06-16	Iniziato	BofA Securities	Buy
2022-04-28	Iniziato	Credit Suisse	Outperform
2022-02-18	Iniziato	William Blair	Outperform
2022-02-07	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-31	Iniziato	Cowen	Outperform
2022-01-07	Iniziato	Piper Sandler	Overweight
2021-10-05	Iniziato	Guggenheim	Buy
2021-09-24	Iniziato	Stifel	Buy
2021-06-28	Reiterato	H.C. Wainwright	Buy
2021-06-11	Iniziato	H.C. Wainwright	Buy
2021-05-07	Aggiornamento	ROTH Capital	Neutral → Buy
2021-05-04	Iniziato	RBC Capital Mkts	Outperform
2021-03-04	Iniziato	JMP Securities	Mkt Outperform
2020-12-22	Downgrade	Robert W. Baird	Outperform → Neutral
2020-10-27	Iniziato	Truist	Buy
2020-10-14	Iniziato	Wells Fargo	Overweight
2020-09-18	Iniziato	Goldman	Buy
2020-02-28	Aggiornamento	Oppenheimer	Perform → Outperform
2020-02-14	Downgrade	Wedbush	Outperform → Neutral
2019-11-01	Aggiornamento	Raymond James	Mkt Perform → Outperform
2019-07-09	Iniziato	Robert W. Baird	Outperform
2019-06-10	Iniziato	ROTH Capital	Neutral
2019-05-03	Aggiornamento	Wedbush	Neutral → Outperform
2019-04-12	Iniziato	Evercore ISI	Outperform
2018-11-02	Downgrade	Wedbush	Outperform → Neutral
2018-10-29	Iniziato	Credit Suisse	Neutral
2018-09-21	Iniziato	Raymond James	Mkt Perform
2018-05-15	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2018-03-08	Iniziato	JMP Securities	Mkt Outperform
2017-11-01	Reiterato	Jefferies	Buy
2017-06-22	Ripresa	Jefferies	Buy
2017-03-28	Iniziato	Chardan Capital Markets	Buy
2016-08-05	Aggiornamento	Jefferies	Hold → Buy

Mostra tutto

Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie

06:41 AM

Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st

06:41 AM

06:08 AM

A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance

06:08 AM

04:01 AM

Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat

04:01 AM

04:00 AM

ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat

04:00 AM

Mar 04, 2026

FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive

Mar 04, 2026

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading - MarketBeat

Mar 04, 2026

This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga

Mar 04, 2026

NTLA Stock Upgrade: Jones Trading Raises Intellia Therapeutics t - GuruFocus

Mar 04, 2026

HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat

Mar 04, 2026

Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026 - Meyka

Mar 04, 2026

Mar 03, 2026

Intellia (NTLA) CEO John M. Leonard awarded large option and RSU grants - Stock Titan

Mar 03, 2026

Intellia (NTLA) EVP receives stock awards and small tax-driven share sale - Stock Titan

Mar 03, 2026

Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing - Stock Titan

Mar 03, 2026

Intellia Therapeutics (NTLA) CFO granted stock options and RSUs - Stock Titan

Mar 03, 2026

Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan

Mar 03, 2026

Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes - Stock Titan

Mar 03, 2026

Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units - Stock Titan

Mar 03, 2026

Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group - MarketBeat

Mar 03, 2026

Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat

Mar 03, 2026

NTLA: RBC Capital Raises Price Target to $15, Maintains Sector P - GuruFocus

Mar 03, 2026

Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial - Sahm

Mar 03, 2026

Royal Bank Of Canada Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat

Mar 03, 2026

Wells Fargo Raises Price Target for Intellia Therapeutics (NTLA) to $15 | NTLA Stock News - GuruFocus

Mar 03, 2026

Wells Fargo & Company Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat

Mar 03, 2026

Intellia Therapeutics (NTLA) Highlights Promising Findings in Hereditary Angioedema Treatment - GuruFocus

Mar 03, 2026

Citizens Jmp Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat

Mar 03, 2026

HC Wainwright Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $30.00 - MarketBeat

Mar 03, 2026

Vanguard Group Inc. Acquires 192,651 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat

Mar 03, 2026

Chardan Raises Price Target on Intellia Therapeutics to $27 From $26, Keeps Buy Rating - marketscreener.com

Mar 03, 2026

NTLA Sees Price Target Raised by Citizens, Rating Maintained | N - GuruFocus

Mar 03, 2026

RBC Raises Price Target on Intellia Therapeutics to $15 From $9, Keeps Sector Perform, Speculative Risk - marketscreener.com

Mar 03, 2026

Intellia presents data on experimental gene therapy for hereditary angioedema - Investing.com India

Mar 03, 2026

NTLA: HC Wainwright & Co. Raises Price Target to $30.00 | NTLA S - GuruFocus

Mar 03, 2026

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - Stock Titan

Mar 03, 2026

Demystifying Intellia Therapeutics: Insights From 4 Analyst Reviews - Benzinga

Mar 03, 2026